Literature DB >> 15352075

Improved non-viral transfection of glial and adult neural stem cell lines and of primary astrocytes by combining agents with complementary modes of action.

Rogan B Tinsley1, Melanie J Vesey, Shahram Barati, Robert A Rush, Ian A Ferguson.   

Abstract

BACKGROUND: Rational design of gene vectors for therapeutic applications requires understanding of transfection mechanisms. In this study, multiple transfection assays revealed complementary mechanisms between two commonly used transfection agents. This finding was then exploited to produce improved transfection outcomes. METHODS AND
RESULTS: Rat C6 glial cells, adult rat hippocampal progenitor cells and primary astrocytes were transfected using Lipofectamine (LA) or polyethylenimine (PEI), in vitro. Although LA- and PEI-transfected populations expressed the same total level of transgene product, LA transfected considerably more cells than PEI (approximately 20 vs. 14%). A fluorescently labelled plasmid and time-course analysis, involving both flow cytometry and confocal microscopy, were used to explain this apparent discrepancy. Results showed that LA delivered more plasmid DNA to the cytoplasm and achieved transgene expression in more cells than PEI. In contrast, PEI transfected fewer cells but, on average, produced more transgene product per transfected cell.
CONCLUSIONS: A comparative transfection model was developed to explain these different characteristics. According to this model, transfection is a multistage process with different transfection agents exerting their primary effect at different stages in this process. This model forecast that it should be possible to prepare a chimeric complex with a transfection efficiency that exceeded that achievable with Lipofectamine or polyethylenimine alone. This prediction was tested and shown to hold for glioma cells, primary astrocytes, and adult neural stems cells. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352075     DOI: 10.1002/jgm.584

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

1.  Astrocytic responses to DNA delivery using nucleofection.

Authors:  H Muyderman; W P Yew; B Homkajorn; N R Sims
Journal:  Neurochem Res       Date:  2010-08-21       Impact factor: 3.996

2.  Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase.

Authors:  Annahita Keravala; Brandi K Ormerod; Theo D Palmer; Michele P Calos
Journal:  J Neurosci Methods       Date:  2008-06-17       Impact factor: 2.390

Review 3.  Non-viral gene therapy for spinal cord regeneration.

Authors:  Li Yao; Sheng Yao; William Daly; William Hendry; Anthony Windebank; Abhay Pandit
Journal:  Drug Discov Today       Date:  2012-05-24       Impact factor: 7.851

Review 4.  Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.

Authors:  Chaitanya R Joshi; Vinod Labhasetwar; Anuja Ghorpade
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-03       Impact factor: 4.147

5.  Vinculin tension distributions of individual stress fibers within cell-matrix adhesions.

Authors:  Ching-Wei Chang; Sanjay Kumar
Journal:  J Cell Sci       Date:  2013-05-17       Impact factor: 5.285

6.  Effective gene expression in the rat dorsal root ganglia with a non-viral vector delivered via spinal nerve injection.

Authors:  Ming-Fong Chang; Jung-Hsien Hsieh; Hao Chiang; Hung-Wei Kan; Cho-Min Huang; Luke Chellis; Bo-Shiou Lin; Shi-Chuen Miaw; Chun-Liang Pan; Chi-Chao Chao; Sung-Tsang Hsieh
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

7.  The Comparative Utility of Viromer RED and Lipofectamine for Transient Gene Introduction into Glial Cells.

Authors:  Sudheendra Rao; Alejo A Morales; Damien D Pearse
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

8.  Reaching for the Stars in the Brain: Polymer-Mediated Gene Delivery to Human Astrocytes.

Authors:  Chaitanya R Joshi; Vijay Raghavan; Sivakumar Vijayaraghavalu; Yue Gao; Manju Saraswathy; Vinod Labhasetwar; Anuja Ghorpade
Journal:  Mol Ther Nucleic Acids       Date:  2018-06-28       Impact factor: 8.886

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.